These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15172365)

  • 1. Oral manganese for liver imaging at three different field strengths.
    Thomsen HS; Loegager V; Noergaard H; Chabanova E; Moller JM; Sonne J
    Acad Radiol; 2004 Jun; 11(6):630-6. PubMed ID: 15172365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging liver metastases with a new oral manganese-based contrast agent.
    Chabanova E; Logager V; Moller JM; Dekker H; Barentsz J; Thomsen HS
    Acad Radiol; 2006 Jul; 13(7):827-32. PubMed ID: 16777556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial.
    Chabanova E; Thomsen HS; Løgager V; Moller JM; Brage K; Fogh K; Bovin J; Elmig J
    MAGMA; 2004 Sep; 17(1):28-35. PubMed ID: 15258827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement.
    Rief M; Huppertz A; Asbach P; Franiel T; Schwenke C; Hamm B; Taupitz M; Wagner M
    Invest Radiol; 2010 Sep; 45(9):565-71. PubMed ID: 20644484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.
    Jørgensen JT; Rief M; Brismar TB; Wagner M; Albiin N
    Acta Radiol; 2012 Sep; 53(7):707-13. PubMed ID: 22821959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial clinical experience with oral manganese (CMC-001) for liver MR imaging.
    Thomsen HS; Barentsz JO; Burcharth F; Chabanova E; Dekker HM; Moesgaard F; Moller JM; Leth-Espensen P; Logager V; Takahashi S
    Eur Radiol; 2007 Jan; 17(1):273-8. PubMed ID: 16763790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: phase I clinical trial assessing efficacy and safety.
    Leander P; Golman K; Månsson S; Höglund P
    Invest Radiol; 2010 Sep; 45(9):559-64. PubMed ID: 20644487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blueberry juice: preliminary evaluation as an oral contrast agent in gastrointestinal MR imaging.
    Hiraishi K; Narabayashi I; Fujita O; Yamamoto K; Sagami A; Hisada Y; Saika Y; Adachi I; Hasegawa H
    Radiology; 1995 Jan; 194(1):119-23. PubMed ID: 7997537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral manganese for liver and bile imaging.
    Thomsen HS; Loegager V; Noerrgaard H; Chabanova E; Moller J; Sonne J
    Acad Radiol; 2005 May; 12 Suppl 1():S21-3. PubMed ID: 16106541
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase-based manganese enhanced MRI, a new methodology to enhance brain cytoarchitectural contrast and study manganese uptake.
    Maddage R; Marques JP; Gruetter R
    Magn Reson Med; 2014 Nov; 72(5):1246-56. PubMed ID: 24259029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary MR imaging: first human experience with MnDPDP.
    Lim KO; Stark DD; Leese PT; Pfefferbaum A; Rocklage SM; Quay SC
    Radiology; 1991 Jan; 178(1):79-82. PubMed ID: 1898539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers.
    Albiin N; Kartalis N; Bergquist A; Sadigh B; Brismar TB
    MAGMA; 2012 Oct; 25(5):361-8. PubMed ID: 22399275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose.
    Manka C; Träber F; Gieseke J; Schild HH; Kuhl CK
    Radiology; 2005 Mar; 234(3):869-77. PubMed ID: 15665227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
    Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
    Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased manganese concentration in the liver after oral intake.
    Thomsen HS; Svendsen O; Klastrup S
    Acad Radiol; 2004 Jan; 11(1):38-44. PubMed ID: 14746400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization of bile movement using MRI spin-labeling technique: preliminary results.
    Gonoi W; Akahane M; Watanabe Y; Isono S; Maeda E; Hagiwara K; Ohtomo K
    AJR Am J Roentgenol; 2013 Jul; 201(1):133-41. PubMed ID: 23789667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Optimization of dosage and exam technique in the use of oral contrast media in magnetic resonance].
    Broglia L; Tortora A; Maccioni F; Arpesani R; Marcelli G; Ascarelli A; Rossi P
    Radiol Med; 1999 May; 97(5):365-70. PubMed ID: 10432968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience.
    Krautmacher C; Willinek WA; Tschampa HJ; Born M; Träber F; Gieseke J; Textor HJ; Schild HH; Kuhl CK
    Radiology; 2005 Dec; 237(3):1014-9. PubMed ID: 16237142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats.
    Kreft BP; Baba Y; Tanimoto A; Finn JP; Stark DD
    Radiology; 1993 Feb; 186(2):543-8. PubMed ID: 8421762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.